Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
about
High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection.Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expressionAssociation of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective reviewSequential events of apoptosis involving docetaxel, a microtubule-interfering agent: a cytometric studyPharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy.A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumoursDocetaxel induces moderate ovarian toxicity in mice, primarily affecting granulosa cells of early growing folliclesNovel formulations of taxanes: a review. Old wine in a new bottle?Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancerFarnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells.Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma.Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose.Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy--the SpheroNEO study.BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer.Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis.Docetaxel-associated epiphora.A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies.Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignanciesPharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinomaDocetaxel monotherapy as second-line treatment for pretreated advanced non-small cell lung cancer patients.Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis.Level of evidence for therapeutic drug monitoring of taxanes.Personalizing oncology treatments by predicting drug efficacy, side-effects, and improved therapy: mathematics, statistics, and their integration.Metabolism of the taxanes including nab-paclitaxel.Treatment regimens of classical and newer taxanes.Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer.A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75.Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis.Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer.Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistanceTargeting the stress oncoprotein LEDGF/p75 to sensitize chemoresistant prostate cancer cells to taxanes.Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model.Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report.Specific Biomarkers Are Associated with Docetaxeland Gemcitabine-Resistant NSCLC Cell Lines.The APE1 redox inhibitor E3330 reduces collective cell migration of human breast cancer cells and decreases chemoinvasion and colony formation when combined with docetaxel.
P2860
Q25257484-A45E738C-8B1B-43DF-917A-31C29A89E35AQ28117805-6254133C-7FF6-42AF-A20B-5B9C42F9DB38Q28545175-EF4D23A6-6C1D-4BAD-A096-B7EF5C7ABEE1Q33232548-0B8AD5DB-DEF1-4179-9380-95E0D82255FBQ33303614-A1783075-DB66-4E89-BC47-2DEAC04996CCQ33378865-BA9FF80D-D2CA-46B9-B15D-71D9AEC03424Q33404024-4DBABD73-A684-47D6-9E4F-7BB43869B54BQ34230276-53E183E0-3776-4731-B840-977685E53EF6Q34563540-08BDF6AE-2BFA-4FFD-8D11-17D59596ED8AQ35035596-EE594391-22BC-472C-BBE2-01912A14D2EAQ35091519-64784A6C-3F99-442D-A074-BFFF24CA6FC6Q35219054-50D10A1B-2714-43CF-AEE3-D104137A7140Q35375610-253F4F98-D58D-481D-9F3F-3EC2F7F675B6Q35674153-35E13739-3006-4C83-8316-7623DABC8FADQ35689902-3C5A1D9F-AFFB-4F48-AEFF-8BBD409A6C9AQ35691501-080DA720-3FE3-4A43-80D6-64FB632EF3EEQ35877763-DA0FC770-DE3D-405A-851B-CA72F7767311Q36484970-7F22A1C1-A20F-4C03-9A7F-B203AA7E39E3Q36494207-D613D688-9A41-48FB-B10F-350A5B27C6FEQ36985133-FAC5927C-D7BE-4456-8749-AAF42C42C4C2Q37163139-DDA2E225-D630-4DA1-B4C4-5936C8C136C0Q37170005-485086B9-8A1C-444C-A34F-8E6AF5069289Q37205484-E589E5EC-AD48-4BF4-BE96-B6AF3BF300DFQ37446311-BED19714-FFD5-424B-A9FB-A0C6A9BB67E3Q37536998-E9371FE9-91E5-4D48-9B3C-FE9E9F49D9A6Q37788732-EB6D0277-9C6D-4E0C-9257-D7F31FCB9376Q38194107-9EF4DA6C-0404-408F-AF87-F298CBD7E885Q38267987-F914839E-CD28-46E6-A3F7-E88AA623E994Q38641136-2B1E7108-0176-43FC-B372-0CAC72B8923DQ39360720-17267EF4-46F9-4482-BECE-146399A9BBE6Q39580436-D0E9D7DD-9AD5-418B-A74B-95500ED95A25Q39806758-B422774E-6BFF-4F29-90A5-EA9061287B50Q40209240-3D3AAFEE-C08B-4978-BC03-E8FD9D6C49E1Q41061525-4688B5C1-33CE-49D9-94FF-4D56D213DB14Q41702685-A02433FC-85E1-4368-8890-35A741DFE616Q41829738-50E117E5-B4A2-4A1C-BBB0-5C7445808B69Q41882527-2613BE9B-5012-49C5-8AA1-A37218C5D344Q43028970-3DB784CA-F54B-4FA9-A872-DAAA8FED52D2Q43217708-D5FF3F3A-8ED1-4CD0-9AC7-A2E9A7DA0BD5Q48111990-AFB00214-9D64-455B-BF4E-C8430B5D234C
P2860
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
@ast
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
@en
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
@nl
type
label
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
@ast
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
@en
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
@nl
prefLabel
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
@ast
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
@en
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
@nl
P2093
P1476
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel
@en
P2093
Alex Sparreboom
Carlton K K Lee
Jaap Verweij
Julie R Brahmer
Michael A Carducci
Yelena Zabelina
P304
P356
10.1158/1078-0432.CCR-0842-03
P407
P577
2004-03-01T00:00:00Z